29/08/2014 - 10:51

Actinogen buys Corticrine, pursues dementia treatment

29/08/2014 - 10:51

Bookmark

Save articles for future reference.

Biotech firm Actinogen has signed an agreement to buy pharmaceutical company Corticrine for about $5.75 million, which focuses on the development of treatments for disease modification and prevention in Alzheimer’s dementia.

To read our articles you will need to either login or subscribe.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options